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AIMS
Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and
oncological indications. We postulate that there is room for improvement of dosing, as the optimal immunosuppressive dose in
calcineurin-free regimens is unknown and since the once daily dosing regimen for oncological indications is often associated with
treatment-limiting toxicity.
METHODS
We developed a mechanistic population pharmacokinetic model for everolimus in cancer and transplant patients and explored
alternative dosing regimens.
RESULTS
We found that formulation did not influence bioavailability and that use of >20 mg prednisolone daily increased everolimus
clearance. In transplant patients, the approved dose of 0.75–1 mg twice daily (BID) results in subtherapeutic trough levels
(<6 μg l–1) and that a higher starting dose of 2.25–3 mg BID is required.
CONCLUSION
For oncological indications, our results encourage the investigation of dosing everolimus 3.75 mg BID in terms of superiority in
safety and noninferiority in efficacy.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Everolimus is an effective drug used for prophylaxis of allograft rejection and treatment of various types of cancer,
although in different formulations.
• Treatment of cancer with everolimus is associated with severe toxicity.
• In the transplant setting, it is unknown what the right dose is in calcineurin-free regimens.
WHAT THIS STUDY ADDS
• The interchangeability of everolimus formulations allows further dose optimization.
• In cancer patients, everolimus dose reduction and splitting may result in efficacious treatment with associated with lower
and, potentially, less toxic exposure.
• Higher doses than approved may be required in calcineurin-free regimens in transplant patients for adequate immuno-
suppressive treatment early in therapy.
Introduction
Everolimus is an orally administered immunosuppressive
and antiproliferative drug that inhibits mammalian target of
rapamycin (mTOR) signalling. The immunosuppressive
effect of everolimus is based on the inhibition of T- and B-cell
proliferation, differentiation and antibody production.
Everolimus is used as an immunosuppressive drug to prevent
allograft rejection. mTOR-inhibitors are increasingly used in
immunosuppressive regimens after organ transplantation
due to the unfavourable nephrotoxicity profile of another
class of immunosuppressive drugs, the calcineurin inhibitors
[1–7]. For prophylaxis of allograft rejection with everolimus
in a calcineurin-free regimen, the consensus therapeutic drug
monitoring (TDM) target is a trough level of 6–10 μg l–1 [8]. It
should be noted that, although several studies have proven
the benefits of everolimus in calcineurin-free regimens, it
remains unknown which dose is required to reach the target
of 6–10 μg l–1 and that frequent dose titration is required to
reach this target [8]. Furthermore, everolimus in calcineurin-
free regimens is often coadministered with relatively high
dose steroids (≥20 mg), which induce the cytochrome
P450 isoenzyme 3A4 (CYP3A4), the main enzyme respon-
sible for metabolism of everolimus [9] putting pharmacoki-
netic (PK) target attainment further at risk.
As an oncolytic drug, everolimus is used in the treatment
of several cancers such as advanced renal cell carcinoma,
neuroendocrine tumours, advanced breast cancer and
tuberous sclerosis complex [10, 11]. Everolimus causes,
through binding to the mTOR receptor, inactivation of the
ribosomal S6 kinase 1 (S6 K1). In its turn, S6 K1 stimulates
protein synthesis and cell-cycle progression. Deregulation of
the mTOR pathway occurs in many types of cancer and
inhibition of this pathway with an mTOR-inhibitor results
in tumour growth inhibition [12]. Everolimus inhibits
mTORC1 but also blocks AKT activation via inhibition of
mTORC2 [13]. Although everolimus is an effective agent in
oncology, its use is seriously hampered by its outspoken
toxicity profile, often requiring dose reductions or treatment
discontinuation [14]. A potential explanation for this
difference may be the result of the different dosing regimens
used. Also, while TDM of everolimus is routinely applied in
the immunosuppressive setting, it is still uncommon in
oncological indications, despite a clear relationship between
drug exposure and treatment outcome [8, 15–17].
There is increasing evidence that the everolimus continu-
ous adequate exposure is required for efficacy, pointing to a
prominent role of trough concentrations as a predictor for
efficacy. First, during clinical development of everolimus in
cancer patients, it was found that daily dosing of everolimus
resulted in continuous high mTOR inhibition and better
pharmacodynamic (PD) response, measured as in vivo mTOR
inhibition, as well as better clinical response objectified with
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria, when compared to a weekly schedule, albeit in the
same total dose of 70 mg during 1 week [18–21]. Second, in
mouse xenograft models of renal and breast carcinoma, it
was recently shown that continuous low exposure above
the free unbound concentration associated with 50% inhibi-
tion (IC50) of proliferation, obtained with subcutaneous in-
fusion of everolimus, resulted in similar efficacy as with
standard intermittent oral dosing. The continuous regimen
was as effective but was associated with a lower total dose
and area under the concentration time curve (AUC) [22]
when compared to intermittent dosing. These findings show
that continuous adequate exposure to the mTOR-inhibitor
during a dosing interval is a prerequisite for therapeutic
success and that, therefore, trough levels are likely to be good
PK endpoints to predict efficacy when compared to AUC, a
metric that does not necessarily predict the minimum
concentration. Also, these findings indicate that dose
splitting (e.g. a twice daily schedule instead of once daily)
may be useful to decrease the required total daily dose, while
maintaining the same trough levels and, thus, a durable
mTOR inhibition. Dose splitting will further result in a lower
AUC and peak concentrations, whichmay be useful to reduce
the toxicity associated with everolimus, as also previously
shown for sirolimus, a chemically and pharmacologically
similar drug [23]. It is, however, unclear which twice daily
everolimus dose is required to maintain a durable mTOR
inhibition as achieved with the once daily schedule.
For dose individualization, different tablet sizes may
allow dose individualization without the necessity of inac-
curate tablet splitting and administration of a formulation
independent of indication. Everolimus is available as
Afinitor for treatment of malignancies as 2.5 mg, 5 mg,
7.5 mg and 10 mg tablets and available under the trade
name Certican (Novartis Pharma AG, Basel, Switzerland)
for the prophylaxis of organ rejection as 0.25 mg and
0.75 mg tablets. It remains unknown whether these
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different formulations can be exchanged from a PK point
of view [24].
The aim of our current study was, therefore, two-fold.
First, we aimed to describe the PK of everolimus in transplant
and oncology patients and identify covariates for its PK.
Second, we aimed to develop alternative dosing regimens to
improve treatment of transplant and oncology patients in
silico. For transplant patients, we aimed to develop a dosing
regimen to achieve a target trough level of 6–10 μg l–1, as
required in calcineurin-free regimens. For oncology patients,
we aimed to develop a twice-daily regimen resulting in
comparable trough levels and mTOR inhibition as with the
once-daily regimen, but with a lower total daily dose and,
thus, exposure.
Methods
Study population and PK sampling
The data in our PK study were from patients receiving
everolimus (Afinitor) 10 once daily for treatment of
metastatic thyroid or breast cancer (n = 71) as a part of two
clinical studies (clinicaltrials.gov identifiers NCT01118065
and NCT01948960) as well as from transplant patients from
two studies (Dutch Trial Register: NTR567, NTR1615 and
clinicaltrials.gov identifier NCT02387151), where everolimus
(Certican) was used for prophylaxis of renal allograft
rejection (n = 55). All studies were approved by the medical
ethics committee and all participants provided informed con-
sent. The study populations and specific characteristics were
previously published elsewhere [2, 17, 25]. Rich PK sampling
was performed with approximately eight (or more) sampling
occasions for each individual during a dosing interval to
allow adequate estimation of all relevant PK parameters.
Bioanalysis
Everolimus EDTA whole blood concentrations were quanti-
fied with liquid chromatography coupled with tandem
mass spectrometry assays, validated according to the Euro-
pean Medicines Agency guidelines on bioanalytical method
validation [26], as described previously [27]. The assay
could quantify everolimus concentrations over the range
of 2 to 160 μg l–1, with within-run and between-run accu-
racy and precision of 90–110% across validated range. The
performance of the assay was tested in each analytical
run by incorporating external quality controls of Recipe
or Chromsystems, which met the acceptance criteria
(<15% bias) for all analyses.
PK analysis
Statistics. All whole blood concentration data were log-
transformed before analysis. Population PK modelling was
performed with the non-linear mixed effects modelling
software package NONMEM v7.3, using the Stochastic
Approximation Expectation Maximization estimation method
followed by Importance Sampling (SAEM-IMP) to obtain the
objective function. The residual error was modelled with an
additive error on the log scale, thus approximating a
proportional error. The inter- and intraindividual variability
was modelled using an exponential error model. The 95%
confidence intervals (95% CI) of the parameter estimates
were calculated with the sampling importance resampling
method as recently proposed by Dosne et al. [28] and as
implemented in the software package Perl Speaks Nonmem
4.7.0 [29]. Model development was guided by physiological
plausibility, standard goodness-of-fit plots, visual predictive
checks and the Akaike Information Criterion (AIC) [30].
Prediction-corrected visual predictive checks were constructed
as described by Bergstrand et al., based on 1000 simulations
of the final model [31].
Structural model development. A previously developed
mechanistic population PK model for everolimus in
cancer patients was used as a starting point for our analysis.
This 2-compartment distribution model accounts for the
physiologically plausible relationship between central and
first-pass metabolism with a well-stirred liver model [25].
Everolimus PK are routinely assessed in whole blood. As
everolimus extensively accumulates in erythrocytes [24],
haematocrit (Ht) is a confounder for the whole blood PK of
everolimus. Although, ideally, plasma concentrations of
everolimus are measured, this is impossible for everolimus
as slight haemolysis during blood collection will already re-
sult in spuriously high plasma concentrations. In the previ-
ously developed model, we calculated plasma PK from the
paired observations of whole blood concentrations and Ht,
assuming a fixed erythrocyte-to-plasma accumulation ratio
of 85:15 [25], as reported by themanufacturer for the concen-
tration range usually observed in clinical practice [24].
However, because of known non-linear erythrocyte binding
of everolimus at higher concentrations, we aimed to extend
our model to also capture nonlinear binding as well.
Therefore, specific and nonspecific everolimus erythrocyte
binding constants were determined from in vitro blood
distribution data from the manufacturer [24]. Nonlinear
erythrocyte binding was captured from a graph showing
distribution of [3H]everolimus between erythrocytes and
plasma vs. everolimus concentration over a concentration
range of 5–5000 ng ml–1 in whole blood using Webplot
digitizer 3.11 [32]. For the derivation of the nonlinear
erythrocyte binding of everolimus, we assumed a Ht of 45%
(v/v) in the source data of healthy volunteers and we fitted
the data to equation (1) by means of least squares regression:
Crb ¼ Bmax  Cp
Kd þ Cp þ KnsCp (1)
In this equation, Crb is the everolimus erythrocyte
concentration, Bmax is the maximal everolimus concentra-
tion specifically bound to erythrocytes, Kd is the predicted
dissociation constant, Kns is the constant expressing non-
specific binding of everolimus to erythrocytes and Cp is the
plasma concentration [33]. In the population PK analysis,
we calculated the plasma concentrations from the paired
observations of whole blood concentrations and Ht using
the derived values for Bmax, Kd and Kns. All parameter
estimates of the PK model are, therefore, shown as the
respective plasma PK parameters.
Delay in drug absorption after ingestion was modelled
with a chain of four transition compartments. The mean
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absorption time (MAT) was estimated and the rate constant
(ktr) for these transition compartments was calculated using
equation (2):
ktr ¼ nþ 1ð Þ=MAT (2)
In this equation, n is the number of transition compart-
ments (n = 4).
The well-stirred liver model was implemented as
described previously [25]. We estimated the apparent intrin-
sic clearance (CLint) and assumed a liver blood flow (QH) of
90 l h–1 and calculated liver volume (VL) as a function of body
size and age, with the equation proposed by Small et al. [34].
The liver plasma flow (QHP) was calculated from liver blood
flow and Ht with equation (3):
QHP ¼ QH  1 –Htð Þ (3)
Hepatic extraction (EH) was defined calculated with
equation (4).
EH ¼ CLint  fuð Þ= QHP þ CLint  fuð Þ½  (4)
In this equation fu is the known concentration indepen-
dent unbound fraction of 0.27 with an interindividual
variability of 3% [35].
The apparent hepatic plasma clearance (CLH) was
calculated with equation (5).
CLH ¼ EH QHP (5)
To account for impact of body size as a confounder for PK
a priori, all flow parameters (hepatic blood flow QH of 90 l h
–1
and intercompartmental clearance Q) as well as the volume
parameters central volume (VC) and peripheral volume (Vp)
were allometrically scaled to body size. We compared the
performance of measured total body weight, as well as the
calculated normal fat mass and fat-free mass as size descrip-
tors for this purpose, as recently described by Holford et al.
[36] during base model development.
The rate constants describing the PK model are summa-
rized below:
k12 = k23 = k34 = k45 = k56 = 5/MAT
k60 = CLH / VL
k67 = (QHP×(1-EH))/VL
k76 = QHP / VC
k78 = Q / VC
k87 = Q / VP
A schematic depiction of the model can be found in
Figure 1. The NONMEM control stream for reference is pro-
vided in supplemental material S2.
Covariate analysis. After development of the base model,
we investigated the impact of drug formulation (Certican
vs. Afinitor) on relative bioavailability as a binary covariate.
Furthermore, we investigated the use of high daily dose
prednisolone (≥20 mg) as a binary covariate on intrinsic
clearance, as it is a known inducer of cytochrome p450
isoenzyme 3A4 (CYP3A4) isoenzyme, the main responsible
enzyme for the metabolism of everolimus [37]. A covariate
was included in the model when it was physiologically
plausible, significantly improved model fit (P < 0.05) and
if the effect was considered clinically relevant, with a cut-
off for relevancy of 25% change in a PK parameter. The P
value was calculated from the reduction in objective
function. A reduction of 3.84 corresponds to a P < 0.05
(from chi squared distribution with one degree of
freedom). A 25% change in PK was considered a clinically
relevant change, based on the fact that smaller dose units
are required for dose individualization for oncological
indications, and that for this indication everolimus is not
considered a drug with a narrow therapeutic window by
the European Medicines Agency everolimus product-
specific bioequivalence guidance [38].
As our PK data were not specifically collected for a covari-
ate analysis, we performed an a posteriori power analysis to
assure that our data were adequate for the proposed covariate
analysis, as proposed earlier [39, 40]. For this purpose, we
simulated for each covariate 500 virtual studies with a covar-
iate effect (25% change in PK) and performed a re-estimation
to calculate the power at a significance level of 5%. This
power calculation was implemented in the Stochastic Simula-
tion and Estimation option in Perl Speaks Nonmem [41].
Figure 1
Schematic depiction of the pharmacokinetic model
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Investigation of improved dosing regimens. For prophylaxis of
allograft rejection in a calcineurin-free regimen, the consensus
PK target is a whole blood trough level of 6–10 μg l–1 at steady
state [8] to assure adequate immunosuppression with limited
toxicity during twice daily dosing of everolimus. This is
underlined by the fact that in most randomized clinical trials
with a regimen of everolimus in absence of calcineurin
inhibitors; however, the average whole blood everolimus
trough level at the end of the study was found to be 7 μg l–1
[2, 3, 42]. For exploration of an improved dosing regimen for
this indication, we simulated the typical steady state PK curve
for everolimus in whole blood in the approved dose of
0.75 mg and 1 mg twice daily. If these dosing regimens did
not result in target trough levels of 6–10 μg l–1, we explored
other twice daily dosing regimens to reach this target.
For oncological indications, it has been reported that
everolimus PK correlate with efficacy and toxicity [16]. How-
ever, there is currently no specific PK target known to aim for
during treatment. However, as the approved dosing regimen
of 10 mg is known to result in an effective treatment we,
therefore, simulated the typical whole blood trough level
associated with everolimus dosed 10 mg once daily to
determine the trough level associated with clinical efficacy.
Also, as inhibition of S6 kinase 1 (S6 K1), a downstream
effector of mTOR and a well-established PD biomarker of
everolimus [43], directly relates with everolimus plasma PK,
we calculated the corresponding S6 K1 inhibition in tumour
tissue as described previously [25]. Since increasing the
dosing frequency will allowmaintaining similar trough levels
with a lower total daily dose, we simulated various twice daily
regimens to obtain the twice daily dose associated with
trough concentrations and tumour S6 K1 inhibition
comparable to the once daily schedule. All simulations were
performed assuming PK steady state in a typical individual
of age 40 years, total body weight 70 kg, height 1.8 m and
Ht 45%.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY [44], and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 [45].
Table 1
Baseline characteristics of included patients
Number Mean Median Standard deviation Minimum Maximum
Renal transplant recipients 55
Male 38
Female 17
Age (years) 53 55 14.0 19 74
Length (cm) 175 175 9.3 153 191
Weight (kg) 81 79 13.7 52 110.3
Ht (fraction) 0.35 0.36 0.04 0.28 0.45
Everolimus Dose (twice daily) 2.4 3 0.74 1.5 3
Prednisolone dose (total daily dose) 14.5 10 6 7.5 40
Total number of PK samples 347
Number of PK samples per patient 6.3 7 1.2 1 7
Metastatic thyroid or breast cancer patients 71
Male 20
Female 51
Age (years) 61 62 10.0 37 80
Length (cm) 170 168 8.9 152 189
Weight (kg) 73.1 73 12.6 45 105
Ht (fraction) 0.38 0.38 0.05 0.25 0.50
Everolimus Dose (once daily) 10 10 10 0 10 10
Prednisolone dose (total daily dose) 0 0 0 0 0
Total number of PK samples 893
Number of PK samples per patient 12.6 12 5.8 3 21
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Results
Study population
A summary of the population characteristics is shown in
Table 1. In short, these populations consisted of patients
on everolimus for treatment of cancer or prophylaxis of
renal allograft rejection. In these populations, everolimus
was used in line with the drug label and the use of strong
inhibitors or inducers of CYP3A4 or p-glycoprotein were
prohibited. Tacrolimus was used as comedication besides
everolimus and prednisolone in 22 renal transplant recipi-
ents who received alemtuzumab induction therapy, the
other renal transplant recipients were patients on everoli-
mus and prednisolone combination therapy. Other comedi-
cation that was used in the renal transplant population were
statins (atorvastatin, pravastatin, simvastatin, rosuvastatin),
sulfamethoxazole/trimethoprim, calcium antagonists (with-
out CYP3A inhibition) and proton pump inhibitors
(pantoprazole, omeprazole and esomeprazole). All data were
selected without prior intervention with TDM. This allowed
unbiased estimation of the PK parameters [46].
Base model development
The everolimus blood binding constants Bmax, Kd and Kns
were estimated to be 0.964, 0.0920 and 0.153 mg l–1,
respectively. The predicted relationship between erythrocyte
and plasma concentrations, together with the observed
plasma and erythrocyte concentrations is shown in supple-
mental material S1. In total, we had 1239 PK observations
available in 126 individuals. Everolimus PK were well-
described with the previously developed two-compartment
disposition model [25]. We observed considerable intra-
individual variability in absorption. No inter-individual
variability could be estimated for VP and Q. Furthermore,
estimated fat-free mass best described the relationship of PK
with body size. Therefore, fat-free mass was used for
allometric scaling of flow and volume parameters in the base
model. The parameter estimates of the base model are shown
in Table 2.
Power and covariate analysis
In our population, we had 82% and 64% power, respectively,
to detect a 25% change in bioavailability as a result of
formulation or in apparent intrinsic clearance as a result of
use of high-dose prednisolone. In the covariate analysis,
only concomitant use of high-dose (≥20 mg) prednisolone
was identified as a significant covariate and it increased
apparent intrinsic clearance with 31% (95% CI 9–51%).
Formulation did not explain variability in relative bioavail-
ability or absorption rate. Therefore, only high-dose pred-
nisolone was included as covariate for intrinsic clearance
in the final model.
Final model evaluation
The final model parameter estimates are shown in Table 2. All
parameter estimates could be reliably estimated, as shown in
the narrow 95% CI of the parameter estimates. Shrinkage for
the variability parameters as well as the residual error was
<30%, indicating that the data were informative for descrip-
tion of variability. Standard goodness-of-fit plots of the final
model are shown in Figure 2. As seen in the prediction-
corrected visual predictive check (Figure 2A,B), the simulated
data corresponded well the observed data, because the
observed 10th, 50th and 90th percentile of the data matched
with the predicted percentiles for both oncology and trans-
plant patients. Furthermore, the plots showing the observed
Table 2
Parameter estimates for the base and final model
Base model Final model
Estimate 95% CI Estimate 95% CI
MAT (h) 0.451 0.393–0.508 0.404 0.347–0.457
CLint (l h
–1) 364 344–386 340 319–362
Increase in CLint due high dose prednisolone (%) - - 31 9.10–55.8
VC (L) 176 158–193 175 157–193
VP (L) 577 546–613 577 542–609
Q (l h–1) 86.4 80.3–92.0 85.7 80.3–91.5
QH (l h
–1) 90 (FIX) - 90 (FIX) -
Interindividual variability CLint (%) 35.2 30.4–39.4 33.9 29.4–38.2
Interindividual variability VC (%) 40.0 39.4–48.4 40.6 29.3–50.0
Intraindividual variability MAT (%) 103 86.6–121 110 90.9–127
Residual variability (%) 17.5 16.6–18.2 17.9 17.0–18.7
All pharmacokinetic parameters are shown as the respective plasma pharmacokinetic parameters. All volume and flow parameters are allometrically
scaled to a fat-free mass of 57.2 kg, corresponding with the fat-free mass of a man with a total body weight of 70 kg and a length of 1.80 m and
should be interpreted as apparent volumes and flows, since the absolute bioavailability of everolimus is unknown. FIX means this parameter was not
estimated, but fixed.
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vs. (individually) predicted whole blood concentrations
(Figure 2F,G) show that the data are narrowly scattered
around the line of unity. Figure 2E, showing the conditional
weighted residuals vs. Ht, shows an even distribution of the
residuals, demonstrating an unbiased prediction of whole
blood concentrations over a wide range of Ht. The NONMEM
control stream for the analysis has been included in supple-
mentary material S2.
Alternative dosing regimens
For use of everolimus in the transplantation setting with a
calcineurin-free regimen, our model predicted that the
approved doses of 0.75 mg and 1 mg twice daily resulted
in steady state whole blood trough levels of 2.37 and
3.16 μg l–1, respectively. Notably, these trough levels are
well-below the target trough level of 6–10 μg l–1 required
for optimal treatment response. In combination with high
dose (≥20 mg) prednisolone these trough levels were
predicted to be even lower at 1.75 and 2.33 μg l–1. To obtain
an everolimus whole blood trough level of approximately
7 μg l–1 without concomitant use of high dose (≥20 mg)
prednisolone, the dose had to be increased to 2.25 mg twice
daily (resulting in a trough level of 6.70 μg l–1) and to 3 mg
twice daily in combination with high dose (≥20 mg) pred-
nisolone to reach the PK target (resulting in a trough level
of 7.01 μg l–1). The typical steady state PK curves in whole
blood, with or without high dose (≥20 mg) prednisolone,
for the 0.75, 1, 2.25 and 3 mg twice daily regimens are
shown in Figure 3.
For oncological indications, the predicted whole blood
trough level and corresponding tumour S6 K1 inhibition
Figure 2
Goodness of fit plots of the final everolimus model. (A) prediction-corrected visual predictive check for everolimus in cancer patients. The black
dots are the individual observed data points. The dashed lines connect the observed 5th, 50th and 95th percentiles per bin. The grey areas are
the 95% confidence interval of the simulated percentiles. (B) Prediction-corrected visual predictive check for everolimus in renal transplant pa-
tients. The black dots are the individual observed data points. The dashed lines connect the observed 5th, 50th and 95th percentiles per bin.
The grey areas are the 95% confidence interval of the simulated percentiles. (C) Conditional weighted residuals vs. population predicted whole
blood concentration. (D) Conditional weighted residuals vs. time after dose. (E) Conditional weighted residuals vs. Ht. (F) Observed concentration
vs. population predicted concentrations. (G) Observed concentration vs. individual predicted concentrations
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for the approved 10 mg once daily dose were 12.3 μg l–1
and 89.9%, respectively. The peak concentration was
68.8 μg l–1 associated with a maximum S6 K1 inhibition
of 96%. When the daily dose of 10 mg was reduced to
7.5 mg and divided in two separate administrations
(3.75 mg twice daily), we predicted a whole blood trough
concentration of 11.7 μg l–1, with a corresponding S6 K1
inhibition of 89.6%. The peak concentration was reduced
almost a twofold in this twice daily dosing regimen at
34.2 μg l–1, but with only a limited decrease in S6 K1 inhi-
bition of 94%. This shows that mTOR inhibition is at a pla-
teau level in these concentrations. These results indicate
that with a 25% lower total dose, administered twice daily,
a similar mTOR inhibition can be maintained as in the ap-
proved dose of 10 mg once daily. To allow comparison, the
predicted PK and PD profiles during a dosing interval in
oncology patients for the approved and alternative dosing
regimen are shown in Figure 4.
Discussion
For the first time, we describe the population PK of everoli-
mus independent of its indication. In our analysis, we did
not find any impact of formulation on bioavailability.
Although absence of evidence is not evidence of absence,
we showed that we had a high power to detect a clinically
relevant difference in relative bioavailability. A clinical
implication of our findings may therefore be that both the
Certican (available as 0.25 and 0.75 mg tablets) and Afinitor
(available as 2.5, 5 and 10 mg tablets) formulations may be
used interchangeably to obtain an optimal individualized
dose without the necessity of inaccurate tablet splitting.
Secondly, we found that the approved twice daily dose of
0.75 mg or 1 mg is inadequate to reach the PK target (a whole
blood trough level of 6–10 μg l–1) for calcineurin-free
regimens in solid organ transplant patients. To prevent
subtherapeutic exposure early in immunosuppressive
Figure 2
(Continued)
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therapy, we suggest increasing the initial dose to 2.25 mg
twice daily when administered without or 3 mg twice daily
when dosed concomitantly with high dose (≥20 mg) prednis-
olone. Although TDM is routinely applied in transplant pa-
tients, resulting in dose titration after treatment, giving the
proposed dose a prioriwill result in faster PK target attainment
after start of treatment.
For oncological indications, we found that similar whole
blood trough levels and durable S6 K1 inhibition could be
maintained as with the approved once daily 10 mg dose with
a 25% lower daily dose when administered as 3.75 mg every
12 h. This dosing regimenwas also associated with an approx-
imate twofold reduction in maximum concentration. Al-
though once daily dosing is often preferred over twice daily
dosing for reasons of treatment adherence [47], we think that
it has been shown for the transplant setting that twice daily
dosing of everolimus is feasible and that, therefore, this is
an attractive regimen to potentially decrease toxicity and
treatment costs, without compromising efficacy, also for on-
cological indications.
Although our predictions show that, on a population
level, everolimus dosing can be improved, it does not over-
come the necessity of dose individualization by means of
clinical and TDM, considering the high variability in PK and
treatment response in both oncology and transplant patients
[8, 48]. In clinical practice, it is most likely that PK and PD var-
iability will be further reduced, due to dose tailoring during
treatment guided by TDM or clinical response.
We recently demonstrated that variability in Ht causes
variability in whole blood PK of everolimus, without affect-
ing plasma concentrations or S6 K1 inhibition [25].
Therefore, when performing TDM by measurement of
whole blood concentrations, measured whole blood
concentrations should be corrected for Ht, to allow compar-
ison with reference values. This is especially relevant con-
sidering the high variability in Ht in patients treated with
everolimus [49], as well as the fact that everolimus itself
may cause anaemia [50]. We advise to calculate the plasma
concentrations from the paired observations of whole blood
concentrations and Ht using our derived relationship
between plasma and erythrocyte concentrations, since it is
more representative of the pharmacologically active
(unbound) plasma concentrations. The target trough level
of 6–10 μg l–1 for adequate immunosuppression in a whole
blood sample with a Ht of 45% would correspond to a
plasma concentration of 1.1–1.9 μg l–1. The typical whole
blood trough concentration of 11.7 μg l–1 associated with
the once daily 10 mg dose in cancer patients would corre-





Typical steady-state pharmacokinetic curves of everolimus in whole blood. The dotted horizontal lines indicate pharmacokinetic target, a trough
level of 6–10 μg l–1. The dashed line indicates the typical pharmacokinetic curve when co-administered with high dose (≥20mg) prednisolone, the
solid line indicates the typical pharmacokinetic curve when administered without prednisolone. (A) Dose 0.75mg twice daily. (B) Dose 1 mg twice
daily. (C) Dose 2.25 mg twice daily. (D) Dose 3 mg twice daily
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Our study may have several limitations. First, in our
model, we assume similar erythrocyte binding for all individ-
uals. It is known, however, that some drugs may be displaced
from erythrocytes by other drugs [51]. Although there is
currently no evidence that displacement of everolimus from
erythrocytes may occur, altered erythrocyte binding kinetics
could result in biased predictions of everolimus plasma
concentrations. In our analysis we assume that potential PK
differences are a result of different drug formulation for the
different indications. In our mechanistic PK analysis, we
corrected for the potential confounders body size by allome-
tric scaling as well as for differences in Ht. To rule out any
effect of population or indication on the PK of everolimus, a
prospective PK cross-over study is required to investigate the
impact of formulation on everolimus PK. Our study consisted
of a heterogeneous population. One might argue that this a
shortcoming of our study. Nonetheless, we think that a PK
study in a real-world heterogeneous setting is of added value
as it may be better representative of the clinical situation.
We have focused our analysis on everolimus and not on its
metabolites. Although everolimus is not known to have
active metabolites [24], several metabolites have been
identified [52] and their exact role in predicting efficacy or
side effects has not yet been established. The use of strong
CYP3A inhibitors or inducers was prohibited in our popu-
lation. With regard to the other comedications used
[tacrolimus, statins (atorvastatin, pravastatin, simvastatin,
rosuvastin), sulfamethoxazole/trimethoprim, calcium an-
tagonists (without CYP3A4 inhibition), proton pump in-
hibitors (pantoprazole, omeprazole and esomeprazole)]
several publications have shown no significant influence
everolimus PK [8, 9]. Prednisolone, by contrast, is known
to induce CYP3A activity in the gut and liver and was,
therefore, specifically tested for effect on everolimus PK.
The role of PK/PD modelling during early drug develop-
ment of everolimus has been pivotal for its development for
oncological indications. Preclinical PK/PD modelling was
performed to link mTOR-inhibition to PK and this PK/PD-
model was then validated in humans and used to guide
dosing in early clinical trials in cancer patients [18, 43]. In
our analysis we have developed a semi-mechanistic PK model
and linked the previously established relationships between
exposure and outcome to devise alternative dosing regimens.
Although application of our model for use of Bayesian dose
tailoring by means of TDM was not a purpose of our analysis,
the developed model could be used for this purpose. The
predictive performance of the model for the desired PK target
(e.g. trough levels) should then be prospectively assessed
before implementation in the clinic.
Together with the recent study by Verheijen et al. [53],
who showed that dose splitting everolimus 10 mg once
daily in 5 mg twice daily resulted in lower maximum con-
centrations, our findings encourage a prospective study in
cancer patients investigating everolimus 10 mg once daily
vs. 3.75 mg twice daily in terms of noninferiority for
efficacy and superiority for toxicity. Furthermore, the use
of 2.25 mg everolimus [or 3 mg in combination with high
dose (≥20 mg) prednisolone] twice daily in the transplant
setting should be prospectively investigated in terms of PK
target attainment after treatment initiation as well as safety
and efficacy.
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